Osaka, Japan

Shizuka Ono

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2013-2020

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Shizuka Ono: Innovator in Pharmaceutical Chemistry

Introduction

Shizuka Ono is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target various diseases. With a total of three patents to her name, her work has the potential to impact therapeutic strategies for immune diseases and cancer.

Latest Patents

One of her latest patents is the "Ethane-sulfonate salt of quinoline derivative." This invention relates to a specific compound that exhibits Axl-inhibiting activity, making it useful as a prophylactic and therapeutic agent for immune diseases and cancer. Another notable patent is the "Acid-addition salt of Trk-inhibiting compound." This compound selectively inhibits Trk-related diseases and demonstrates excellent solubility and absorbability, which are crucial for effective treatment.

Career Highlights

Shizuka Ono has worked with notable companies in the pharmaceutical industry, including Ono Pharmaceutical Co., Ltd. Her experience in these organizations has allowed her to refine her skills and contribute to innovative solutions in drug development.

Collaborations

Throughout her career, Shizuka has collaborated with esteemed colleagues such as Takahiro Nekado and Hideomi Kijima. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Shizuka Ono's contributions to pharmaceutical chemistry through her innovative patents highlight her role as a key inventor in the field. Her work continues to pave the way for advancements in therapeutic agents for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…